Mesothelioma in Situ: The Key to Early Detection and Curative Strategies

ByHolly Zink
Mesothelioma in Situ: The Key to Early Detection and Curative Strategies

Pleural mesothelioma is a rare and aggressive cancer that affects the pleura, the thin lining surrounding the lungs. It is primarily caused by exposure to asbestos fibers, with symptoms often not appearing until decades after exposure. It is aggressive and has a poor prognosis. Finding it early is crucial. This improves patient outcomes.

In recent years, interest in finding early precancerous mesothelioma, including mesothelioma in situ, has grown. This early stage of the disease is a chance. It’s a chance to improve how we diagnose it and how we treat it in many ways. Diagnosing pleural mesothelioma at the in-situ phase means finding the disease before it has spread. This may lead to curative treatment options.

Challenges and Opportunities in Early Diagnosis

Mesothelioma in situ has posed challenges for diagnosis and management. It was identified as a new histological entity in 2021. Many aspects remain open. They include how to diagnose the disease, how likely and when it is to get worse, the need for follow-up, and the role of early surgery.

This narrative review aims to provide a comprehensive overview of mesothelioma in situ. It covers its definition, risk factors, diagnostic criteria, and challenges associated with early detection. It also shows how important it is to find mesothelioma in situ. It also shows future uses for managing it in the context of pleural mesothelioma care.

One of the key aspects of managing mesothelioma in situ is the need for a multidisciplinary approach. This involves teamwork. It’s between oncologists, pathologists, radiologists, and surgeons. They work to ensure accurate diagnosis and treatment planning. Finding mesothelioma early may allow for simpler treatments, like surveillance or localized therapies. These treatments could improve patient outcomes and quality of life.

Mesothelioma in situ is a crucial stage. It is key for finding and treating pleural mesothelioma. Research and improvements in diagnosis and treatment are crucial. They will improve outcomes for patients with this devastating disease. Using many types of expertise is key. It helps treat mesothelioma in place and give patients the best care and outcomes.

Source:

Danuzzo, Federica, Federico Raveglia, Francesca Spinelli, Chiara Maria Sibilia, Enrico Cassina, Lidia Libretti, Emanuele Pirondini, et al. “Pleural Mesothelioma in Situ: A Comprehensive Review.” European Journal of Cancer Prevention: The Official Journal of the European Cancer Prevention Organisation (ECP), March 11, 2024. https://doi.org/10.1097/CEJ.0000000000000883.

 

 

Similar Posts

  • |

    Mesothelioma Blood Test May Be Possible

    ByAlex Strauss

    An international team of researchers is studying the proteins found on the surface of cancer cells in an effort to improve mesothelioma diagnosis. The team, made up of scientists from the US, Switzerland, Italy and Chile, has just published their findings on a new kind of test to identify protein-derived mesothelioma biomarkers in blood serum. Mesothelioma is an aggressive cancer of the membranes around organs. Because the most common mesothelioma biomarker, mesothelin, is also overproduced by other kinds of cancer cells, it has only limited diagnostic value. A test to identify a set of proteins produced specifically by mesothelioma cells could greatly improve diagnostic accuracy. Led by Ferdinando Cerciello and Bernd Wollscheid of the Institute of Molecular Systems Biology in…

  • | |

    Needle Biopsy “Simple, Safe & Accurate” for Mesothelioma

    ByAlex Strauss

    Mesothelioma researchers in China say a biopsy method that involves a single skin puncture can produce good diagnostic results for mesothelioma patients with little pain or risk. The study focused on percutaneous (through the skin) biopsy in patients who had unexplained fluid buildup or swelling in their abdomens. Abdominal distension and fluid buildup (called ascites) can be signs of peritoneal mesothelioma, a rare but aggressive cancer of the abdominal lining caused by exposure to asbestos. Peritoneal mesothelioma accounts for less than 30% of all mesothelioma cases. Because the symptoms may be vague and often develop many decades after asbestos exposure, peritoneal mesothelioma can be especially challenging to diagnose.  Misdiagnosis and under-diagnosis are not uncommon. In the newest study on percutaneous…

  • | |

    Inflammation Both “Friend and Foe” in Mesothelioma

    ByAlex Strauss

    An immune system response that causes mesothelioma symptoms such as fever, fatigue, and weight loss may also be helpful to clinicians as a way to find and treat the disease. Scientists with The Asbestos Diseases Research Institute in Sydney, Australia make that case that both systemic inflammation (throughout the body) and at the site of a tumor – has long been associated with mesothelioma and other cancers. Inflammation results when the body attempts to address the imbalances of cancer by producing more of certain immune system cells. Some inflammatory markers, such as CD+8 T-cells and C-reactive protein, have been linked to better prognosis in mesothelioma. Other inflammatory markers, such as certain macrophages and a high neutrophil-to-lymphocyte ratio, can signal the…

  • | |

    FDG PET-CT Results Could Lead to Improved Mesothelioma Treatment

    ByAlex Strauss

    In a recent study, researchers say a better understanding of certain diagnostic criteria could result in more targeted treatments for malignant mesothelioma. In a recent published report, doctors from the medical school at Dicle University in Diyarbakir, Turkey measured the relationship between PET-CT scan results and survival in 177 patients with malignant pleural mesothelioma. The patients were diagnosed between April 2007 and April 2011. They had a mean age of 55.4 and most (56%) were male. Patients in the study all had FDG PET-CT scans before beginning their mesothelioma treatment. FDG PET-CT scanning is a powerful imaging tool for mesothelioma and other cancers that combines a radioactive tracer with a combination of positron emission tomography and computed tomography scanning.  Because…

  • | |

    Mesothelioma Surgeons Report New Biopsy Technique

    ByAlex Strauss

    A team of surgeons in Maryland have demonstrated how using a standard biopsy tool in a new way could improve the biopsy process for certain mesothelioma patients. An aggressive cancer of the pleural lining around the lungs, malignant pleural mesothelioma usually requires a tissue biopsy to make a definitive diagnosis. Often this is done using a rigid tool called a thoracoscope inserted into the chest wall while the patient is under general anesthesia. However, mesothelioma doctors at Walter Reed National Military Medical Center detail the case of a 79-year-old suspected mesothelioma patient whose biopsy was done in a minimally-invasive way, under conscious sedation, thanks to the novel use of a standard tool. Although the patient had several of the common signs…

  • |

    New Serum Marker Could Improve Mesothelioma Diagnosis

    ByAlex Strauss

    Japanese researchers believe they have found a way to diagnose a rare form of mesothelioma earlier using a simple blood test. Diffuse malignant peritoneal mesothelioma (DMPM), which represents about a fourth of all mesothelioma cases, is an aggressive malignancy that spreads across the lining of the abdomen. In most cases, DMPM is lethal within a year. The standard treatment for diffuse malignant peritoneal mesothelioma is cytoreductive surgery to remove as much of the mesothelioma as possible, followed by intraperitoneal chemotherapy to destroy residual cancer cells. In some studies, this approach has resulted in 5-year survival rates of 30 to 60 percent. However, it is most successful when it is performed early, while the primary mesothelioma tumor is more easily removed. Like all forms of…